
In 2025, state attorneys general (AGs) are at the forefront of an aggressive wave of enforcement against intoxicating hemp products. With federal oversight lacking clear direction—and hemp-derived cannabinoids like delta–8, HHC, and THCP proliferating—AGs across the United States have filled the regulatory vacuum. Their primary tools? Unfair or Deceptive Acts or Practices (UDAP) statutes, cease-and-desist orders, and state-level settlement agreements that impose significant restrictions on multi-state cannabis and hemp brands.
This article analyzes recent AG enforcement trends, highlights common UDAP theories and settlement playbooks, and provides a compliance toolkit for brands navigating this fast-changing legal terrain.
The 2018 Farm Bill opened the door to legal hemp-derived cannabinoids, but with minimal guidance for regulating synthetic and psychoactive derivatives. Courts—including the 9th and 4th Circuits—have generally sided with industry arguments that such compounds are legal if derived from hemp and kept below 0.3% delta-9 THC. However, federal agencies like the FDA have not directly enforced against these products—leaving the field to state AGs, especially where youth use or health risks are implicated.
AG coalitions have also weighed in on cannabis policy issues, urging Congress to address intoxicating products and supporting individual state bans or restrictions.
UDAP (Unfair or Deceptive Acts or Practices) statutes exist in nearly all states. While originally intended to protect consumers from fraud, these statutes are being leveraged to challenge allegedly misleading marketing, mislabeling, and deceptive product claims on hemp-derived cannabinoids.
Key UDAP Theories Used by State AGs in 2025:
In March 2025, Nebraska's Attorney General Mike Hilgers launched a sweeping action against delta-8 and synthetic THC products, issuing cease-and-desist letters to more than 100 Omaha-area retailers. The AG cited findings that over 90% of products tested failed labeling accuracy or compliance checks, with several targeting minors through flavor and packaging.
AG Hilgers offered settlement agreements requiring:
Other AGs in states including Florida, Indiana, and Texas have followed suit with warnings, product seizures, or direct enforcement focused on similar UDAP violations.
For multistate brands, an AG investigation now often leads to settlement orders with far-reaching impacts:
Brands must be prepared to respond to AG inquiries within tight windows—sometimes under 2 weeks—often including an immediate product hold and document production demands.
1. Audit All Product Labels and COAs
2. Implement True Age Verification
3. Cut Child Appeal: Review Flavors, Imagery, and Ad Placements
4. Add Impairment and Safety Disclaimers
5. Develop an AG Letter Response Playbook
Intoxicating hemp products remain a policy flashpoint as federal lawmakers continue to debate Farm Bill reforms and regulators spar over the boundary between "cannabis" and "hemp." In the meantime, expect:
Compliance for multi-state brands is no longer about minimum federal standards. It’s about meeting the most robust requirements across all relevant states—a moving target in 2025 as AGs use UDAP theories to push the outer edge of hemp enforcement.
For tailored, up-to-the-minute guidance and operational resources on cannabis compliance, multi-state licensing, and hemp regulation, rely on CannabisRegulations.ai—your trusted partner in a fast-shifting regulatory landscape.

In 2025, state attorneys general (AGs) are at the forefront of an aggressive wave of enforcement against intoxicating hemp products. With federal oversight lacking clear direction—and hemp-derived cannabinoids like delta–8, HHC, and THCP proliferating—AGs across the United States have filled the regulatory vacuum. Their primary tools? Unfair or Deceptive Acts or Practices (UDAP) statutes, cease-and-desist orders, and state-level settlement agreements that impose significant restrictions on multi-state cannabis and hemp brands.
This article analyzes recent AG enforcement trends, highlights common UDAP theories and settlement playbooks, and provides a compliance toolkit for brands navigating this fast-changing legal terrain.
The 2018 Farm Bill opened the door to legal hemp-derived cannabinoids, but with minimal guidance for regulating synthetic and psychoactive derivatives. Courts—including the 9th and 4th Circuits—have generally sided with industry arguments that such compounds are legal if derived from hemp and kept below 0.3% delta-9 THC. However, federal agencies like the FDA have not directly enforced against these products—leaving the field to state AGs, especially where youth use or health risks are implicated.
AG coalitions have also weighed in on cannabis policy issues, urging Congress to address intoxicating products and supporting individual state bans or restrictions.
UDAP (Unfair or Deceptive Acts or Practices) statutes exist in nearly all states. While originally intended to protect consumers from fraud, these statutes are being leveraged to challenge allegedly misleading marketing, mislabeling, and deceptive product claims on hemp-derived cannabinoids.
Key UDAP Theories Used by State AGs in 2025:
In March 2025, Nebraska's Attorney General Mike Hilgers launched a sweeping action against delta-8 and synthetic THC products, issuing cease-and-desist letters to more than 100 Omaha-area retailers. The AG cited findings that over 90% of products tested failed labeling accuracy or compliance checks, with several targeting minors through flavor and packaging.
AG Hilgers offered settlement agreements requiring:
Other AGs in states including Florida, Indiana, and Texas have followed suit with warnings, product seizures, or direct enforcement focused on similar UDAP violations.
For multistate brands, an AG investigation now often leads to settlement orders with far-reaching impacts:
Brands must be prepared to respond to AG inquiries within tight windows—sometimes under 2 weeks—often including an immediate product hold and document production demands.
1. Audit All Product Labels and COAs
2. Implement True Age Verification
3. Cut Child Appeal: Review Flavors, Imagery, and Ad Placements
4. Add Impairment and Safety Disclaimers
5. Develop an AG Letter Response Playbook
Intoxicating hemp products remain a policy flashpoint as federal lawmakers continue to debate Farm Bill reforms and regulators spar over the boundary between "cannabis" and "hemp." In the meantime, expect:
Compliance for multi-state brands is no longer about minimum federal standards. It’s about meeting the most robust requirements across all relevant states—a moving target in 2025 as AGs use UDAP theories to push the outer edge of hemp enforcement.
For tailored, up-to-the-minute guidance and operational resources on cannabis compliance, multi-state licensing, and hemp regulation, rely on CannabisRegulations.ai—your trusted partner in a fast-shifting regulatory landscape.